Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Stefania Demuro, Rita Maria Concetta Di Martino, José Antonio Ortega, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 9098-9098
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

DYRK1A inhibitors for disease therapy: Current status and perspectives
Tong Liu, Yuxi Wang, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114062-114062
Closed Access | Times Cited: 72
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Robert Roskoski
Pharmacological Research (2022) Vol. 183, pp. 106362-106362
Closed Access | Times Cited: 59
Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
Siew Lee Cheong, Jian Kai Tiew, Yi Hang Fong, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1560-1560
Open Access | Times Cited: 43
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
Mattias F. Lindberg, Emmanuel Deau, Jonas Arfwedson, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4106-4130
Closed Access | Times Cited: 25
Spatiotemporal patterns of locus coeruleus integrity predict cortical tau and cognition
Elisenda Bueichekú, Ibai Díez, Chan Mi Kim, et al.
Nature Aging (2024) Vol. 4, Iss. 5, pp. 625-637
Open Access | Times Cited: 12
The Omnipresence of DYRK1A in Human Diseases
Estelle Deboever, Alessandra Fistrovich, Christopher Hulme, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9355-9355
Open Access | Times Cited: 35
Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
Anna Sampietro, F. Javier Pérez-Areales, Paula Felippe Martinez, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 545-545
Open Access | Times Cited: 32
Challenges in Discovering Drugs That Target the Protein–Protein Interactions of Disordered Proteins
Judit Oláh, Tibor Szénási, Attila Lehotzky, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1550-1550
Open Access | Times Cited: 28
The role of glycogen synthase kinase 3 beta in neurodegenerative diseases
Honglu Yu, Min Xiong, Zhentao Zhang
Frontiers in Molecular Neuroscience (2023) Vol. 16
Open Access | Times Cited: 19
Fyn Kinase in Alzheimer’s Disease: Unraveling Molecular Mechanisms and Therapeutic Implications
Shreyasi Meur, Dipanjan Karati
Molecular Neurobiology (2024)
Closed Access | Times Cited: 5
A multi enzyme study reviewing the role of target enzymes in Alzheimer’s disease and unveiling potential inhibitors with insights on their present and future assessment
Sanaa Zaki, Samiullah Khan, Ruhi Ali
Medicinal Chemistry Research (2025)
Closed Access
Identification of potential inhibitors of Fyn-Kinase from bioactive phytochemicals of Berberis lycium for therapeutic targeting of neurodegenerative disease
Sneh Prabha, Arunabh Choudhury, Juhi Saraswat, et al.
Journal of Biomolecular Structure and Dynamics (2025), pp. 1-18
Closed Access
An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease
Xin Liu, Lingyun Lai, Jiang-xia Chen, et al.
Neuropharmacology (2023) Vol. 232, pp. 109525-109525
Closed Access | Times Cited: 13
Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects
Zimeng Cheng, Tianyue Han, Jingtong Yao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116065-116065
Closed Access | Times Cited: 12
Natural compounds from herbs and nutraceuticals as glycogen synthase kinase‐3β inhibitors in Alzheimer's disease treatment
Zheng Zhao, Ye Yuan, Shuang Li, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 8
Open Access | Times Cited: 4
Regulatory mechanisms of tetramethylpyrazine on central nervous system diseases: A review
Yue Liu, Guang Yang, Wenqiang Cui, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 19
Lability of the Nrf2/Keap/ARE Cell Defense System in Different Models of Cell Aging and Age-Related Pathologies
Gregory A. Shilovsky
Biochemistry (Moscow) (2022) Vol. 87, Iss. 1, pp. 70-85
Closed Access | Times Cited: 18
Qingxin Kaiqiao Fang decreases Tau hyperphosphorylation in Alzheimer's disease via the PI3K/Akt/GSK3β pathway in vitro and in vivo
Shuo Liu, Luting Xu, Yan Shen, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 117031-117031
Open Access | Times Cited: 8
Triaging between post-translational modification of cell cycle regulators and their therapeutics in neurodegenerative diseases
Neetu Rani, Mehar Sahu, Rashmi K. Ambasta, et al.
Ageing Research Reviews (2023) Vol. 94, pp. 102174-102174
Closed Access | Times Cited: 8
miR-26a is a Key Therapeutic Target with Enormous Potential in the Diagnosis and Prognosis of Human Disease
Wei Guan, Yan Chen, Yan Fan
Current Medicinal Chemistry (2024) Vol. 31, Iss. 18, pp. 2550-2570
Closed Access | Times Cited: 2
Establishment of the Diagnostic Signature of Ferroptosis Genes in Multiple Sclerosis
Yang Yang, Qianqian Bai, Fangfei Liu, et al.
Biochemical Genetics (2024)
Open Access | Times Cited: 2
Emerging pharmaceutical therapies of Ascidian-derived natural products and derivatives
K. Cooreman, Bart De Spiegeleer, Christof Van Poucke, et al.
Environmental Toxicology and Pharmacology (2023) Vol. 102, pp. 104254-104254
Open Access | Times Cited: 7
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
Alberto M. Martelli, Francesca Paganelli, Camilla Evangelisti, et al.
Cells (2022) Vol. 11, Iss. 11, pp. 1812-1812
Open Access | Times Cited: 10
Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β
Jin-Hee Park, Jeong-Woo Hwang, Hyunju Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Anti-oxidant effects of cannabidiol relevant to intracerebral hemorrhage
Gaili Yan, Xiangyu Zhang, Hongmin Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top